JPWO2022235759A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2022235759A5 JPWO2022235759A5 JP2023567910A JP2023567910A JPWO2022235759A5 JP WO2022235759 A5 JPWO2022235759 A5 JP WO2022235759A5 JP 2023567910 A JP2023567910 A JP 2023567910A JP 2023567910 A JP2023567910 A JP 2023567910A JP WO2022235759 A5 JPWO2022235759 A5 JP WO2022235759A5
- Authority
- JP
- Japan
- Prior art keywords
- immunoglobulin
- equine
- locus
- rodent
- variable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000283073 Equus caballus Species 0.000 claims description 129
- 241000283984 Rodentia Species 0.000 claims description 85
- 108090000623 proteins and genes Proteins 0.000 claims description 81
- 108060003951 Immunoglobulin Proteins 0.000 claims description 79
- 102000018358 immunoglobulin Human genes 0.000 claims description 79
- 230000009261 transgenic effect Effects 0.000 claims description 44
- 210000004027 cell Anatomy 0.000 claims description 39
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 claims description 36
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 34
- 238000000034 method Methods 0.000 claims description 34
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 claims description 22
- 239000013598 vector Substances 0.000 claims description 21
- 108091026890 Coding region Proteins 0.000 claims description 16
- 230000001225 therapeutic effect Effects 0.000 claims description 15
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 claims description 12
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 claims description 12
- 230000006798 recombination Effects 0.000 claims description 11
- 238000005215 recombination Methods 0.000 claims description 11
- 230000001105 regulatory effect Effects 0.000 claims description 11
- 108010065825 Immunoglobulin Light Chains Proteins 0.000 claims description 10
- 102000013463 Immunoglobulin Light Chains Human genes 0.000 claims description 10
- 238000004519 manufacturing process Methods 0.000 claims description 9
- 108010052160 Site-specific recombinase Proteins 0.000 claims description 8
- 238000011144 upstream manufacturing Methods 0.000 claims description 7
- 239000000427 antigen Substances 0.000 claims description 6
- 108091007433 antigens Proteins 0.000 claims description 6
- 102000036639 antigens Human genes 0.000 claims description 6
- 238000010367 cloning Methods 0.000 claims description 6
- 102000016897 CCCTC-Binding Factor Human genes 0.000 claims description 4
- 108010014064 CCCTC-Binding Factor Proteins 0.000 claims description 4
- 101100351020 Mus musculus Pax5 gene Proteins 0.000 claims description 4
- 108010076504 Protein Sorting Signals Proteins 0.000 claims description 4
- 101150117115 V gene Proteins 0.000 claims description 4
- 101100351021 Xenopus laevis pax5 gene Proteins 0.000 claims description 4
- 230000003213 activating effect Effects 0.000 claims description 4
- 210000000628 antibody-producing cell Anatomy 0.000 claims description 4
- 210000004408 hybridoma Anatomy 0.000 claims description 4
- 108010091086 Recombinases Proteins 0.000 claims description 3
- 102000018120 Recombinases Human genes 0.000 claims description 3
- 102000012745 Immunoglobulin Subunits Human genes 0.000 claims description 2
- 108010079585 Immunoglobulin Subunits Proteins 0.000 claims description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 25
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 10
- 108020004414 DNA Proteins 0.000 description 9
- 108700026244 Open Reading Frames Proteins 0.000 description 9
- 108010051219 Cre recombinase Proteins 0.000 description 7
- 108020004705 Codon Proteins 0.000 description 6
- 241000124008 Mammalia Species 0.000 description 6
- 108091092195 Intron Proteins 0.000 description 5
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 5
- 229930182817 methionine Natural products 0.000 description 5
- 229950010131 puromycin Drugs 0.000 description 5
- 230000014621 translational initiation Effects 0.000 description 4
- 108091035707 Consensus sequence Proteins 0.000 description 3
- 108010046276 FLP recombinase Proteins 0.000 description 3
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 3
- 108020004440 Thymidine kinase Proteins 0.000 description 3
- 230000000692 anti-sense effect Effects 0.000 description 3
- 238000012217 deletion Methods 0.000 description 3
- 230000037430 deletion Effects 0.000 description 3
- 239000013604 expression vector Substances 0.000 description 3
- 102000016607 Diphtheria Toxin Human genes 0.000 description 2
- 108010053187 Diphtheria Toxin Proteins 0.000 description 2
- 108010090227 Immunoglobulin kappa-Chains Proteins 0.000 description 2
- 102000012960 Immunoglobulin kappa-Chains Human genes 0.000 description 2
- 102100029620 Immunoglobulin lambda constant 2 Human genes 0.000 description 2
- 108010004020 Immunoglobulin lambda-Chains Proteins 0.000 description 2
- 229930193140 Neomycin Natural products 0.000 description 2
- 241000700584 Simplexvirus Species 0.000 description 2
- 108091081024 Start codon Proteins 0.000 description 2
- 239000003999 initiator Substances 0.000 description 2
- 230000000869 mutational effect Effects 0.000 description 2
- 229960004927 neomycin Drugs 0.000 description 2
- 230000008488 polyadenylation Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 230000005030 transcription termination Effects 0.000 description 2
- 241000701022 Cytomegalovirus Species 0.000 description 1
- 101800001224 Disintegrin Proteins 0.000 description 1
- YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 1
- 101000834253 Gallus gallus Actin, cytoplasmic 1 Proteins 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical class C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- 108700005091 Immunoglobulin Genes Proteins 0.000 description 1
- 102000005741 Metalloproteases Human genes 0.000 description 1
- 108010006035 Metalloproteases Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 101000579126 Mus musculus Phosphoglycerate kinase 1 Proteins 0.000 description 1
- 108091092724 Noncoding DNA Proteins 0.000 description 1
- 241001505332 Polyomavirus sp. Species 0.000 description 1
- 108091008109 Pseudogenes Proteins 0.000 description 1
- 102000057361 Pseudogenes Human genes 0.000 description 1
- 108091081062 Repeated sequence (DNA) Proteins 0.000 description 1
- 102000006601 Thymidine Kinase Human genes 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 238000010363 gene targeting Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163184440P | 2021-05-05 | 2021-05-05 | |
| US63/184,440 | 2021-05-05 | ||
| PCT/US2022/027622 WO2022235759A1 (en) | 2021-05-05 | 2022-05-04 | Transgenic rodents expressing chimeric equine-rodent antibodies and methods of use thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024516996A JP2024516996A (ja) | 2024-04-18 |
| JPWO2022235759A5 true JPWO2022235759A5 (https=) | 2025-05-14 |
| JP2024516996A5 JP2024516996A5 (https=) | 2025-05-14 |
Family
ID=81750504
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023567910A Pending JP2024516996A (ja) | 2021-05-05 | 2022-05-04 | トランスジェニック哺乳動物およびその使用方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20240215556A1 (https=) |
| EP (1) | EP4333613A1 (https=) |
| JP (1) | JP2024516996A (https=) |
| KR (1) | KR20240004503A (https=) |
| CN (1) | CN117440753A (https=) |
| AU (1) | AU2022268937A1 (https=) |
| CA (1) | CA3216988A1 (https=) |
| IL (1) | IL307638A (https=) |
| WO (1) | WO2022235759A1 (https=) |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1293460C (en) | 1985-10-07 | 1991-12-24 | Brian Lee Sauer | Site-specific recombination of dna in yeast |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5175384A (en) | 1988-12-05 | 1992-12-29 | Genpharm International | Transgenic mice depleted in mature t-cells and methods for making transgenic mice |
| GB8904009D0 (en) | 1989-02-22 | 1989-04-05 | Celltech Ltd | Vector |
| US5464764A (en) | 1989-08-22 | 1995-11-07 | University Of Utah Research Foundation | Positive-negative selection methods and vectors |
| US6689610B1 (en) | 1989-08-22 | 2004-02-10 | University Of Utah Research Foundation | Cells and non-human organisms containing predetermined genomic modifications and positive-negative selection methods and vectors for making same |
| US6673986B1 (en) | 1990-01-12 | 2004-01-06 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US7041871B1 (en) | 1995-10-10 | 2006-05-09 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| ATE352612T1 (de) | 1990-08-29 | 2007-02-15 | Pharming Intellectual Pty Bv | Homologe rekombination in säugetier-zellen |
| US5789650A (en) | 1990-08-29 | 1998-08-04 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5877397A (en) | 1990-08-29 | 1999-03-02 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5874299A (en) | 1990-08-29 | 1999-02-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| WO1992015694A1 (en) | 1991-03-08 | 1992-09-17 | The Salk Institute For Biological Studies | Flp-mediated gene modification in mammalian cells, and compositions and cells useful therefor |
| DE4228162C1 (de) | 1992-08-25 | 1994-01-13 | Rajewsky Klaus Dr | Verfahren zum Ersetzen homologer Genabschnitte aus Säugern in der Keimbahn von nicht-menschlichen Säugern |
| US5593598A (en) | 1994-04-20 | 1997-01-14 | Mcginness; Michael P. | Method and apparatus for closed loop recycling of contaminated cleaning solution |
| US6091001A (en) | 1995-03-29 | 2000-07-18 | Abgenix, Inc. | Production of antibodies using Cre-mediated site-specific recombination |
| US6130364A (en) | 1995-03-29 | 2000-10-10 | Abgenix, Inc. | Production of antibodies using Cre-mediated site-specific recombination |
| EP1500329B1 (en) | 1996-12-03 | 2012-03-21 | Amgen Fremont Inc. | Human antibodies that specifically bind human TNF alpha |
| US6774279B2 (en) | 1997-05-30 | 2004-08-10 | Carnegie Institution Of Washington | Use of FLP recombinase in mice |
| FR2814642B1 (fr) | 2000-10-03 | 2005-07-01 | Ass Pour Le Dev De La Rech En | Souris transgenique pour la recombinaison ciblee mediee par la cre-er modifiee |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| US7422889B2 (en) | 2004-10-29 | 2008-09-09 | Stowers Institute For Medical Research | Dre recombinase and recombinase systems employing Dre recombinase |
| ATE536374T1 (de) * | 2006-09-01 | 2011-12-15 | Therapeutic Human Polyclonals Inc | Erhöhte expression von humanem oder humanisiertem immunglobulin bei nicht-humanen transgenen tieren |
| JP6482757B2 (ja) * | 2010-07-26 | 2019-03-13 | トリアンニ インコーポレイテッドＴｒｉａｎｎｉ，Ｉｎｃ． | トランスジェニック動物および使用方法 |
| GB2528811A (en) * | 2011-05-06 | 2016-02-03 | Nvip Pty Ltd | Anti-nerve growth factor antibodies and methods of preparing and using the same |
| US20170058052A1 (en) | 2015-08-24 | 2017-03-02 | Trianni, Inc. | Enhanced production of immunoglobulins |
| GB2561352B (en) * | 2017-04-10 | 2023-01-18 | Genome Res Ltd | Animal models and therapeutic molecules |
| GB2578867A (en) * | 2018-10-09 | 2020-06-03 | Genome Res Ltd | Animal models and therapeutic molecules |
| CA3144956A1 (en) * | 2019-07-01 | 2021-01-07 | Trianni, Inc. | Transgenic mammals and methods of use |
| WO2021003152A1 (en) * | 2019-07-01 | 2021-01-07 | Trianni, Inc. | Transgenic mammals and methods of use thereof |
-
2022
- 2022-05-04 AU AU2022268937A patent/AU2022268937A1/en active Pending
- 2022-05-04 IL IL307638A patent/IL307638A/en unknown
- 2022-05-04 CA CA3216988A patent/CA3216988A1/en active Pending
- 2022-05-04 JP JP2023567910A patent/JP2024516996A/ja active Pending
- 2022-05-04 KR KR1020237038920A patent/KR20240004503A/ko active Pending
- 2022-05-04 CN CN202280033146.9A patent/CN117440753A/zh active Pending
- 2022-05-04 EP EP22725093.3A patent/EP4333613A1/en active Pending
- 2022-05-04 WO PCT/US2022/027622 patent/WO2022235759A1/en not_active Ceased
- 2022-05-04 US US18/557,414 patent/US20240215556A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2021200079B2 (en) | Animal models and therapeutic molecules | |
| AU2009298458B2 (en) | Non-human mammals for the production of chimeric antibodies | |
| DK2553100T3 (en) | REPLACING NON-HUMAN ANIMALS TO CREATE CHIMERARY ANTIBODIES | |
| DK2825036T3 (en) | Histidine engineered light chain antibodies and genetically modified rodents to generate them | |
| RS59076B1 (sr) | Glodari koji eksprimiraju imunoglobulinske sekvence senzitivne na ph | |
| WO2019182751A1 (en) | Transgenic chicken that produces human antibodies | |
| JPWO2022235759A5 (https=) | ||
| JP2024543248A (ja) | トランスジェニック哺乳動物およびその使用方法 | |
| JP2024516996A (ja) | トランスジェニック哺乳動物およびその使用方法 | |
| HK40058709B (en) | Rodent models and therapeutic antibodies | |
| HK40060958B (en) | Rodent models and therapeutic molecules | |
| JPWO2023090361A5 (https=) | ||
| JPWO2023086815A5 (https=) | ||
| HK40014468A (en) | Rodent models and therapeutic molecules | |
| HK1184966A (en) | Animal models and therapeutic molecules | |
| HK1180535B (en) | Animal models and therapeutic molecules |